Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nanjing Iaso Biotherapeutics and Innovent Biologics have received China National Medical Product Administration (NMPA) approval for Fucaso (equecabtagene autoleucel) as a treatment for patients with relapsed or refractory multiple myeloma who have received ≥3 lines of prior therapies.
The first and only approved anti-amyloid Alzheimer's Disease (AD) treatment shown to reduce the rate of disease progression and slow cognitive impairment has been granted approval by the FDA.
SMi Systems, a company specializing in single molecule imaging and quantification technologies, has disclosed a £6m seed funding round to develop the utility of a novel multi-omic platform for in vitro diagnosis and biomedical research.
PrecisionLife, a techbio company driving precision medicine in complex chronic diseases, has announced a data access agreement with the University of Oxford to spearhead new treatments for endometriosis.
A microbiome therapeutic developed by the Danish biotech company Freya Biosciences has achieved promising topline results in a phase 1 trial in women with asymptomatic vaginal tract dysbiosis.